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90 The Journal of Thoracic and Cardiobjectives: Bicuspid aortic valve is a common condition and is associated with a
ignificantly increased risk of developing thoracic aortic aneurysms and acute aortic
issection. Patient-specific prediction of the risk of developing thoracic aortic
neurysm, however, is imprecise. We hypothesize that genotypic variations in
atients with bicuspid aortic valves contribute to this observed variability in aortic
henotype. We, therefore, investigated the potential relationship between mutations
n regions of NOTCH1 recently reported to be associated with bicuspid aortic valve
nd the phenotype of bicuspid aortic valve and thoracic aortic aneurysms in
nrelated patients undergoing surgical repair.
ethods: We performed a targeted mutational analysis of NOTCH1 using genomic
NA from 48 unrelated subjects with concomitant bicuspid aortic valve and
horacic aortic aneurysm using denaturing high-performance liquid chromatography
nd DNA sequencing. We focused on exons in which mutations associated with
icuspid aortic valve have been reported previously. Results were compared with
ontrol subjects with trileaflet aortic valves (n  94), bicuspid aortic valves, and
ormal aortas (n  22) and in subjects with tricuspid aortic valves and thoracic
ortic aneurysms (n  28).
esults: Four unique, nonsynonymous (3 novel) variants were identified in 5
10.4%) of 48 patients with concomitant bicuspid aortic valves and thoracic aortic
neurysms compared with only 3 (2.1%) of 144 control subjects (P .02). Of these,
novel missense mutations, A1343V and P1390T, were observed only in patients
ith bicuspid aortic valves and tricuspid aortic aneurysms.
onclusions: This targeted analysis involving NOTCH1 exons previously impli-
ated in familial and sporadic bicuspid aortic valve demonstrates overrepresentation
f NOTCH1 missense variants among patients with bicuspid aortic valves and
horacic aortic aneurysms. Identification of aneurysm-predisposing susceptibility
enes may lead to gene-directed surgical therapy of the ascending aorta for patients
ith bicuspid aortic valves.
icuspid aortic valve (BAV) disease is the most common congenital cardio-
vascular malformation and is responsible for a large proportion of patients
coming to aortic valve replacement (AVR).1 Individuals with BAV are at
ncreased risk of developing thoracic aortic aneurysms (TAA), acute aortic dissec-
ion, and premature death relative to the normal population2 and have a demonstra-
ly higher incidence of postoperative aortic dissection after AVR.3 Accordingly,
ome surgeons advocate prophylactic replacement of an “even seemingly normal”
scending aorta at the time of AVR for BAV.3 Aneurysmal disease does not develop
n all patients with BAV, however, and such an approach would needlessly subject
 large number of patients to a procedure with a predictably higher operative risk.4
linical risk stratification, however, is imprecise.
vascular Surgery ● August 2007
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DBoth TAA disease and BAV disease are inheritable dis-
rders in at least some cases. Familial clustering of BAV
isease shown by Clementi,5 Cripe,6 and their colleagues
as demonstrated heritability (h2) of 89% with autosomal
ominant transmission and incomplete penetrance of the
ondition. In addition to Marfan syndrome and the more
ecently identified Loeys–Dietz syndrome,7 a genetic basis
or some cases of familial TAA and dissection has been
apped by Milewicz, Basson, and their colleagues to 3
enetic loci: 5q13-14,8 11q23,9 and 3p24-25,10,11 the last of
hich has proven to be the transforming growth factor
TGF) -2 receptor.
Recently, an association between mutations in NOTCH1
nd aortic valve disease has been described. NOTCH1 en-
odes for a transmembrane protein that activates a signaling
athway with an active role in cardiac embryogenesis, in-
luding aortic and pulmonary valve development as well as
he development and maintenance of the aorta and other
reat vessels.12-15 Garg and colleagues16 reported NOTCH1
utations in 2 pedigrees with an assortment of cardiovas-
ular disease phenotypes, including BAV. Subsequently,
ohamed and coworkers17 reported 2 mutations in different
xons of the same gene in patients with nonfamilial BAV;
owever, the status of the aorta was not described in the
ormer and only briefly mentioned in the latter study. To
ate, no studies have identified genetic mutations common
o both BAV and TAA phenotypes.
Recent advances in the field of genomics introduce the
ossibility of genetic profiling as is currently used in phar-
acogenomics. Identification of genes predictive of TAA in
atients with BAV may foster “gene-directed” surgical ther-
py of the ascending aorta. We hypothesize that genetic
ariability among patients with BAV may explain the phe-
otypic variability in the subset of patients with BAV in
hom TAA develops. We, therefore, performed a targeted
utational analysis of NOTCH1 from genomic DNA ob-
ained from patients with BAV and TAA using denaturing
igh-performance liquid chromatography (DHPLC) and di-
ect DNA sequencing. These results were compared with
NA from 188 reference alleles obtained from control
Abbreviations and Acronyms
AVR  aortic valve replacement
BAV  bicuspid aortic valve
DHPLC denaturing high-performance liquid
chromatography
PCR  polymerase chain reaction
TAA  thoracic aortic aneurysm
TAV  trileaflet aortic valve
TGF  transforming growth factorubjects (n  94) with normal, trileaflet aortic valves i
The Journal of ThoracicTAV), as well as a limited number of subjects with BAV
nd normal aortas (n  22) or TAV and TAA (n  28).
aterials and Methods
fter institutional review board approval, written informed con-
ent was obtained for all 192 unrelated subjects. We performed a
argeted mutational analysis of the 4 exons (11, 20, 25 and 29)
reviously implicated in aortic valve disease16,17 in 48 unrelated
atients with combined BAV and TAA. Comparisons were made
mong subjects with BAV and normal aortas (n  22), TAV and
AA (n  28), and reference alleles from control subjects with
AV (n  94) as seen in Figure 1.
We defined an abnormal aorta as an ascending aorta that
easured more than 4.0 cm at its greatest diameter. DNA for all
AV and TAA subjects was extracted either from peripheral
ymphocytes using the Puregene DNA extraction kit (Gentra, Inc,
inneapolis, Minn) or from aortic tissue obtained at the time of
urgery (Wizard SV genomic DNA purification system; Promega
orp, Madison, Wis). Genomic DNA for 94 subjects with TAV
as acquired from patients residing in Olmsted County, Minne-
ota, participating in an epidemiologic heart disease study.18 Echo-
ardiograms were available for control subjects to confirm valve
henotype.
Using polymerase chain reaction (PCR), DHPLC, and direct
NA sequencing, we performed a targeted mutational analysis of
he 4 exons (11, 20, 25, and 29) of NOTCH1 previously implicated
n BAV,16,17 as previously described.19 PCR amplification primers
ere designed with Oligo software (Molecular Biology Insights,
nc, Cascade, Colo). PCR primers are shown in Table 1. In brief,
HPLC is a sensitive method used to elucidate unknown gene
utations. It is based on thermal energy found in the formation and
eparation of double-stranded DNA fragments containing a mis-
atch in the base pairing between the “wild type” and “mutant,”
r heteroduplex, DNA strands. PCR-amplified DNA is injected
nto a solid phase column that is heated to a specific temper-
ture (individually optimized for each unique PCR product),
hich allows for partial denaturing of the DNA sequence of
igure 1. Flow chart of research subjects. DNA was analyzed
rom 192 subjects, BAV/TAA (n  48), BAV with normal aortas
n  22), and TAV/TAA (n  28). BAV, Bicuspid aortic valve; TAV,
rileaflet aortic valve; TAA, thoracic aortic aneurysm.nterest. A linear acetonitrile gradient based on the size of the
and Cardiovascular Surgery ● Volume 134, Number 2 291
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DCR product is applied to the column to flush the DNA strands
nd send the PCR products through an ultraviolet detector,
esulting in a chromatogram showing the sample’s elution pro-
le. Since heteroduplex (mutant sequences) species are less
hermodynamically stable than homoduplexes (normal se-
uences), these double-stranded complexes will begin to un-
avel at the elevated temperature and elute from the column
ooner then their homoduplex or “wild-type” counterparts. As a
esult, “mutant” DNA yields a DHPLC profile that is different
rom the “wild type” profile, enabling the detection of mutation
arboring samples whose precise genetic mutation is then es-
ablished by direct DNA sequencing.
To be regarded as a putative BAV/TAA-susceptibility variant,
he following criteria had to be met. First, the genetic variant had
o be a nonsynonymous variant (synonymous single-nucleotide
olymorphisms were excluded from consideration), resulting in a
redicted change in the translated amino acid. Second, the variant
ad to involve a highly conserved residue. Finally, the variant had
o be absent among 188 reference alleles from control subjects
ith echo-confirmed TAV. Mutations were annotated by the single
etter nomenclature whereby A1343V, for example, designates a
NA alteration producing a missense mutation involving a sub-
titution of an alanine (A) by valine (V) at amino acid position
343.
An in silico analysis was performed with PredictProtein (a
eb-based tool found at www.predictprotein.org) to predict effect
n secondary protein structure.20
Differences in the proportion of patients with DNA sequence
ariations among groups were statistically analyzed with the
isher exact test. Patient demographic data were analyzed with
he Student t test, Wilcoxon rank sum, or Fisher exact test where
ppropriate.
esults
targeted mutational analysis of NOTCH1 was performed
n 192 unrelated patients with BAV/TAA (n  48), BAV
nd normal aorta (n  22), TAV/TAA (n  28), or TAV
nd normal aorta (n  94) who served as reference alleles.
able 2 summarizes the demographic, clinical, and patho-
ogic data for BAV/TAA cases (n  48) and those with
AV/TAA (n  28). Compared with TAV/TAA subjects,
he BAV/TAA patients were more likely male (79% vs
4%; P  .04), had more hypercholesterolemia (40% vs
4%; P  .02), and had smaller aortic aneurysms (50  7
ABLE 1. Primers for screened NOTCH1 exons
rimer sequences Forward primer
ragment
Notch1-11 TCC TCA GGT TGG CAC AGG TG
Notch1-20 TGG CAG ATG TGC GTT CTG AG
Notch1-25A AGG AGA GCG GTG GCA CTG CTG
Notch1-25B TGT GAG CCC ACA TCC GAG AGC
Notch1-25C GCT CCC TCA ACT TCA ATG ACC
Notch1-29 GCC CAC CTC CCA CGC CAGs 57  9 mm; P  .01). BAV disease for the BAV/TAA 4
92 The Journal of Thoracic and Cardiovascular Surgery ● Auguohort demonstrated fusion of the right/left coronary cusps
n 94% of cases and the presence of raphé and valve
alcification in 85% and in 64% of cases, respectively.
Clinical data were not available for the majority of pa-
ients with isolated BAV (n  22) inasmuch as most were
olunteers participating in a study of kindreds with BAV
hose evaluation consisted of only limited 2-dimensional
chocardiography to assign valve phenotype in addition to
onating DNA. Similarly, limited clinical and demographic
ata were available for the 94 subjects whose DNA was
sed as reference alleles inasmuch as they were recruited
rom an epidemiologic heart disease study. Available de-
ographic data for the entire cohort (n  2,031), from
hich our 94 subjects were sampled, are 48% male, mean
ge 62  11 years, and mean body mass index 28.4 
.3 kg/m2.
Overall, 4 unique nonsynonymous (3 novel) variants
ere identified in 5 of 48 (10.4%) patients with BAV/TAA
ompared with only 3 of 144 (2.1%) patients with normal
ortas (2/94 reference DNA with trileaflet valves, 1/28
AV/TAA, and 0/22 with BAV/normal aortas; P  .02).
able 3 summarizes the clinical characteristics and phe-
otype of the NOTCH1 mutation-positive patients with
AV/TAA. Of the 5 patients (3 men, average age 52 
2 years, average aortic dimension 50  5 mm) with
OTCH1 variants, 3 had fusion of the right and left
oronary cusps, 3 presented with raphé, 4 underwent
VR, and 2 had evidence of aortic valve calcification.
nly 1 of these 5 patients had a family history of either
AV or TAA (patient 1, Table 3). This patient, a 70-
ear-old woman with BAV and a 57-mm ascending aorta,
ad a family history of both BAV and TAA. We identi-
ed both polymorphisms, R1350L and P1377S, in this
atient. No other patients with DNA sequence variants
ad family histories of either BAV or TAA.
Two novel NOTCH1 missense mutations, A1343V and
1390T, involved conserved residues localized to epider-
al growth factor–like domains and were absent in 188
eference alleles derived from relatively age- and sex-
atched volunteers with echo-confirmed normal TAV
Figure 2). The A1343V mutation was identified in a
Reverse primer Fragment size (bp)
CAC GTG TCG GTC AGT CCT CA 400
AGC AGG TTA CCT TGT CGC TG 239
CCC CGA AGC TGT AGT CCA GGA 387
GGC TGA GTT GCA CTG GCT GTC 331
CCT GAG CAG AGC CTT AGA ACT G 251
GGG AGT GAG CAG AGC CTG TCA 2571-year-old woman who underwent AVR for a stenotic,
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Doncalcified BAV and concomitant graft replacement of
n enlarged ascending aorta. In silico analysis of A1343V
emonstrated conserved residues that predicted a change
n one of the epidermal growth factor–like domains. The
1390T mutation was identified in a 55-year-old man
ho underwent AVR for a stenotic, calcified BAV and
oncomitant reduction aortoplasty of an enlarged ascend-
ng aorta.
Additionally, 2 nonsynonymous polymorphisms, R1350L
nd P1377S, were identified in both patients with BAV/TAA
ABLE 2. Demographic, clinical, and pathologic character
atient characteristics BAV/TAA (n  48) TA
emographic data
Age* 53  12
Gender (% male) 79
omorbidities† %
Hypertension 46
Hypercholesterolemia 40
Smoking 25
Diabetes 8
amily history
Family history of BAV 13
Family history of TAA 6
icuspid valve disease (%)
Cusp fusion (% R/L) 94
Raphé (% present) 85
Calcification (% present) 64
Stenosis 25
Regurgitation 38
Mixed 29
None 8
ortic disease
Aortic dimension (mm)* 50  7
AV, Bicuspid aortic valve; TAV, trileaflet aortic valve; TAA, thoracic ao
Clinical data not available for most subjects with BAV  normal aortas.
 .05 was considered significant.
ABLE 3. Patient clinical characteristics for BAV/TAA pat
atient
Clinical characteristics for patients with missen
Gender
Age
(y)
Valve
status
Cusp
fusion Raphé Calcifi
1 F 70 BAV Unknown Unknown Y
2 M 47 BAV R/L Y N
3 F 41 BAV R/L Y N
4 M 55 BAV R/NC N Y
5 M 47 BAV R/L Y N
issense mutations absent in controls are in bold print. F, Female; M, mal
usp; L, left coronary cusp; NC, noncoronary cusp; AVR, aortic valve replacem
The Journal of Thoracicnd controls. The R1350L substitution was noted in 1 (42%) of
8 BAV/TAA cases and 1 (1%) of 94 trileaflet controls, while
1377S substitution was observed in 3 (6%) of 48 BAV/TAA
ases, 1 (3.6%) of 28 TAV/TAA, and 1 (1%) of 94 trileaflet
ontrols. Both genetic variants localized to epidermal
rowth factor–like domain 35.
Figure 3 i s a topographic summary of DNA sequence
ariants from the targeted NOTCH1 analysis demonstrat-
ng both the missense mutations (A1343V and P1390T)
nd polymorphisms (R1350L and P1377S).
on of patients with BAV/TAA, TAV/TAA, or isolated BAV
(n  28) BAV  normal aorta† (n  22) P value‡
 18 56  17 .05
54 64 .04
%
39 N/A .6
14 N/A .02
25 N/A 1
0 N/A .3
22 .4
18 .3
 9 .01
neurysm; N/A, not available. *Presented as mean  standard deviation.
istical comparisons were made between BAV/TAA and TAV/TAA groups.
with NOTCH1 nonsynonymous variants
tations
Operation Mutationn
Aortic
dimension (cm)
5.7 AVR, graft replacement of
ascending aorta
R1350L
P1377S
5.2 Bentall P1377S
4.5 AVR, graft replacement of
ascending aorta
A1343V
4.5 AVR, reduction aortoplasty P1390T
4.9 Valve-sparing root replacement P1377S
V, bicuspid aortic valve; TAA, thoracic aortic aneurysm; R, right coronaryizati
V/TAA
61
57
rtic a
‡Statients
se mu
catio
e; BA
ent.
and Cardiovascular Surgery ● Volume 134, Number 2 293
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Discussion
he principal finding of this targeted mutation analysis of
he NOTCH1 gene is the overrepresentation of nonsynony-
ous sequence variations and the identification of 2 novel
issense mutations among patients with combined BAV/
AA phenotype. These mutations (A1343V and P1390T)
ere absent in reference alleles and subjects with BAV and
ormal aortas as well as TAV/TAA. Given the purported
oles of the NOTCH1-encoded signaling pathway, we spec-
lated that perhaps genetic variation in NOTCH1 may con-
igure 3. Topographic summary of DNA sequence variants from
argeted mutation analysis of NOTCH1 demonstrating missense
utations (A1343V, P1390T) and polymorphisms (R1350L, P1377S).
olors indicate the exons (11, 20, 25, 29) examined in this targetedcnalysis.
94 The Journal of Thoracic and Cardiovascular Surgery ● Auguer susceptibility for aortic aneurysmal formation, particu-
arly TAA. The findings of the present study support this
otion.
We chose to study the potential association between
OTCH1 and patients with BAV/TAA because it has been
mplicated as a potential susceptibility gene for heritable
ardiovascular disease. Garg and colleagues16 described
OTCH1 mutations in 2 pedigrees with complex, heteroge-
eous cardiac disease including BAV, although the status of
he ascending aorta was not mentioned. Subsequently,
tudying nonfamilial cases, Mohamed and coworkers17 re-
orted variants in 2 of 48 patients with BAV. Although not
he focus of their study, the incidence of NOTCH1 sequence
ariations was 11% (2/18) among the individuals in their
tudy with concomitant BAV/TAA. Given the size of this
ene, we focused our attention on the 4 exons in which
OTCH1 mutations have been reported previously, and this
estricted analysis of NOTCH1 may underestimate the rel-
tive contribution of genetic variation in NOTCH1 to the
evelopment of TAA.
NOTCH1 is a plausible candidate gene for BAV and
AA. Located at 9q34.3, NOTCH1 encodes for a transmem-
rane protein that functions as a transcriptional cofactor to
ctivate the Notch signaling pathway, a signaling pathway
ound in developmental pathways of many organ systems
ncluding the human cardiovascular system.21,22 Specifi-
Figure 2. Molecular characterization
of novel NOTCH1 missense mutations
absent in controls. Depicted are dena-
turing high performance liquid chro-
matography (DHPLC) profiles and DNA
sequences demonstrating NOTCH1 mis-
sense mutations A1343V (A) and B)
P1390T.ally, NOTCH1 has a role in migration of cells from the
st 2007
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Dardiac cushions and cardiac jelly into the conotruncal cush-
ons from which the aortic and pulmonary valves are
ormed.13-15
A role for NOTCH1 mutations in the pathogenesis of TAA
s also plausible. In addition to its role in cardiogenesis and
alvulogenesis, the Notch1 signaling pathway has a role in
evelopment and maintenance of the aorta and other ves-
els.13-15 Additionally, there is increasing evidence of interac -
ion between the Notch1 pathway and TGF.23 This is partic -
larly exciting in light of recent reports of TGF-2 receptor
utations and TAA in syndromal patients such as those with
oeys–Dietz and Ehlers–Danlos syndromes.7 TGF has a
nown role in regulation of extracellular matrix of aortic tissue.
n the basis of the interaction between the Notch1 pathway
valvulogenesis) and TGF (aortic extracellular matrix regu-
ation), we hypothesize that BAV patients with NOTCH1 mu-
ations may be more susceptible to abnormal extracellular
atrix regulation and, therefore, aneurysm formation. Al-
hough the association between TGF receptor mutations and
ortic aneurysm is in its infancy, we believe that exploring an
ssociation between NOTCH1 and TGF in patients with
onsyndromal aortic aneurysms (including patients with BAV/
AA) is certainly intriguing and warranted.
There is increasing interest in the identification of the
enetic determinants of aortic valve disease. In 2005, Garg
nd colleagues16 reported NOTCH1 truncation mutations
R1108X and H1505del) in two families with dominantly
nherited familial aortic valve disease associated with aortic
alve calcification. These deleterious mutations presumably
ause haplo-insufficiency and a loss of function phenotype
f Notch1 signaling. Among a 5-generation pedigree host-
ng the truncation mutation, 7 of 9 family members were
ffected and had calcific aortic stenosis in the setting of
ither BAV or TAV. Recently, Mohamed and colleagues17
dentified NOTCH1 missense mutations in approximately
% of sporadic cases of BAV.
Limitations of the present study include the het-
rogeneity in baseline demographics found among our
ohorts, as well as the challenge of defining “abnormal”
scending aortic phenotype. BAV/TAA patients had a sig-
ificantly greater proportion of males and subjects with
ypercholesterolemia than did subjects with TAV/TAA.
he overall impact this difference makes on interpretation is
nknown but is a limitation of the present study. Addition-
lly, defining significant aortic enlargement in patients with
AV remains problematic. One option is to use established
omograms indexed to body mass index, but these are
mperfect because measurements may change with fluctua-
ions in body mass. We used a liberal definition of ascend-
ng aortic abnormalities at greater than 4.0 cm. If anything,
his may have diluted the observation of overrepresentation
f DNA sequence variants found in the BAV/TAA cohort.
sing a more conservative definition of aortic aneurysm of
The Journal of Thoracic.5 cm or larger, the proportion of DNA variants in the
AV/TAA cohort would increase from 10.4% (5/48) to
2.5% (5/40).
Here, we report the identification of NOTCH1 amino
cid altering variants in 10.4% (5/48) of patients with con-
omitant BAV/TAA, 0 of 22 BAV subjects without aneurys-
al disease, and 1 of 28 patients with TAV/TAA. Although
ot found to be statistically significant owing to the limited size
f our cohort, these data are congruent with recently reported
ata from Mohamed’s group.17 They too identified NOTCH1
issense mutations in 2 (11%) of 18 patients with sporadic
AV and concomitant aortic aneurysm and in none of 30 BAV
atients without aneurysmal disease.
Taken together, these independent investigations suggest
significant overrepresentation of NOTCH1 missense mu-
ations in BAV/TAA (7 of 66 compared with 0 of 52;
 .01). These observations may offer insight into pre-
icting which patients with BAV are at risk for the devel-
pment of TAA. To be sure, these studies warrant further
nvestigation into the role of NOTCH1 missense variants in
he pathogenesis of aneurysmal associated valve disease.
hether these NOTCH1 missense variants lead to a “gain”
r “loss” of function phenotype will require further func-
ional characterization.
Exploration of additional NOTCH1 exons should be in-
luded in future investigations into the role of NOTCH1 in
he extracellular matrix of the ascending aorta.
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